Observational studyDrugs & aging2026
Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients.
Observational study in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTocilizumab (TCZ) is an interleukin-6 receptor inhibitor approved for the treatment of giant cell arteritis (GCA). Biosimilars of TCZ, such as TYENNE™, are biologic agents which are similar to the originator (RoACTEMRA™) in structure, efficacy, and safety. Many indications, including GCA, are extrapolated from pivotal trials in rheumatoid arthritis (RA), supported by pharmacological similarity and immunogenicity data.
objectiveThe objective was to evaluate the effectiveness and safety of switching from originator TCZ (RoACTEMRA™) to biosimilar TCZ (TYENNE™) in patients with GCA managed in routine clinical practice.
methodsThis observational, retrospective, multicenter, real-world study included patients with GCA who switched from RoACTEMRA™ to TYENNE™. Outcomes assessed included clinical and laboratory parameters of disease activity, complete remission, glucocorticoid burden, and safety profile. Comparisons were performed at baseline, 3 months, and 6 months. Linear mixed models and mixed-effects logistic regression were used to assess differences across follow-up visits.
resultsA total of 38 patients (68.4% female; mean age 74.1 years) were included. GCA phenotypes comprised cranial (n = 14; 36.8%), extracranial (n = 14; 36.8%), and mixed presentation (n = 10; 26.3%). Prior exposure to RoACTEMRA™ averaged 36.3 ± 28.4 months. Subcutaneous TCZ was administered in 32 patients (84.2%), while 6 received intravenous therapy. At the time of switch, 92.1% were clinically asymptomatic and 81.6% met criteria for complete remission. TYENNE™ was used as monotherapy in 34 patients (89.5%) and in combination with methotrexate in 4 patients (10.5%). Treatment regimens were preserved in all but one patient who was receiving originator TCZ at a dose of 4 mg/kg every 6 weeks, in whom the dosing interval was spaced from 6 to 8 weeks. After a mean follow-up of 8.2 ± 3.1 months, no significant differences were found in complete remission rates, daily prednisone dose, or inflammatory markers respect to baseline. Retention of biosimilar TCZ was 94.7%. TCZ dosing intervals were extended in four patients (10.5%), and treatment was discontinued in one patient owing to sustained remission. No disease relapses occurred. One patient developed herpes zoster, and another discontinued biosimilar TCZ following diagnosis of diverticulosis.
conclusionsSwitching from originator TCZ (RoACTEMRA™) to biosimilar TCZ (TYENNE™) appears to be safe and effective in patients with GCA in routine clinical practice.
Indexed as
Identifiers
41714460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.